The Immunopathogenesis of Chronic HBV Induced Liver Disease

1982 ◽  
pp. 159-179 ◽  
Author(s):  
Gary A. Levy ◽  
Francis V. Chisari
Keyword(s):  
Liver Disease ◽  
Chronic Hbv

scholarly journals Serum Golgi Protein 73 (GP73) is a Diagnostic and Prognostic Marker of Chronic HBV Liver Disease

Medicine ◽  
2015 ◽  
Vol 94 (12) ◽  
pp. e659 ◽  
Author(s):  
Zhengju Xu ◽  
Liguan Liu ◽  
Xingnan Pan ◽  
Kaipeng Wei ◽  
Meijuan Wei ◽  
...  
Keyword(s):  
Liver Disease ◽  
Prognostic Marker ◽  
Chronic Hbv ◽  
Golgi Protein

scholarly journals Spectrum of Hepatits B Infection Among Patients Attending Liver Unit in Nepalgunj Medical College – Kohalpur

2018 ◽  
Vol 16 (2) ◽  
pp. 2-5
Author(s):  
Dipendra Khadka ◽  
Sudhamshu KC ◽  
Niyanta Karki ◽  
Sandip Khadka ◽  
Kiran Regmi
Keyword(s):  
Liver Disease ◽  
Hepatitis B ◽  
Tertiary Care ◽  
Hbv Dna ◽  
Hbv Infection ◽  
Hepatitis B Infection ◽  
Chronic Hbv Infection ◽  
Medical College ◽  
Liver Unit ◽  
Chronic Hbv

Introduction: Hepatitis B infection is a global problem. Hepatitis B virus (HBV) infection related liver disease is also not an uncommon problem in our country too. Reports regarding pattern of chronic HBV infection are also lacking. The aim of the present study was to determine the spectrum of chronic HBV infection among patients attending the liver clinic in a tertiary care center. Method: A hospital based descriptive cross-sectional study was carried out in Liver unit of Nepalgunj Medical College, Kohalpur, from April 2018 to November 2018. All patients with HBsAg positive were further tested for HBeAg, HBeAb, HBV DNA quantitative and liver function test. Ultrasound examination was advised for any evidence of chronic liver disease. Staging was done according to viral serology, liver biochemistry and ultrasonography of liver Results: Total patients enrolled were 119. Majority of patents were in between 30-60 years (51.3%) with male predominance 59.7%. Most of patients were in the stage of HBeAg negative chronic infection 66.4% with normal transaminase and HBV DNA <2000 IU/ML. Majority of patients having unknown source of infection 90.8%. Incidental detection (67.2%) was common mode of detection. Conclusions: Majority of patients were in HBeAg negative chronic hepatitis B infection phase with normal transaminase and low HBV DNA not requiring treatment.

Fas / FasL system, IL-1β expression and apoptosis in chronic HBV and HCV liver disease

2008 ◽  
Vol 15 (7) ◽  
pp. 515-522 ◽  
Author(s):  
M. Bortolami ◽  
A. Kotsafti ◽  
R. Cardin ◽  
F. Farinati
Keyword(s):  
Liver Disease ◽  
Chronic Hbv

scholarly journals Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection

1999 ◽  
Vol 12 (2) ◽  
pp. 351-366 ◽  
Author(s):  
Francis J. Mahoney
Keyword(s):  
Liver Disease ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hepatitis B Vaccine ◽  
Hbv Infection ◽  
World Health ◽  
Chronic Hbv Infection ◽  
Chronic Hepatitis B Virus ◽  
B Virus ◽  
Chronic Hbv

SUMMARY Acute and chronic hepatitis B virus (HBV) infection is a leading cause of liver disease worldwide. It is estimated that approximately 350 million people worldwide have chronic HBV infection and that 1 million persons die each year from HBV-related chronic liver disease. In the past decade, significant progress in the understanding of the molecular virology and pathogenesis of HBV infection has been made. In addition, effective treatment modalities have been developed for persons with chronic infection. Worldwide, prevention of HBV transmission has become a high priority. In 1992, the Global Advisory Group to the World Health Organization recommended that all countries integrate hepatitis B vaccine into national immunization programs by 1997. Currently, 80 countries have done so and several others are planning to. Many countries have reported dramatic reductions in the prevalence of chronic HBV infection among children born since the hepatitis B vaccine was introduced into infant immunization schedules. Recent reports from Taiwan indicate a reduction in the incidence of liver cancer among children as a result of widespread hepatitis B vaccination programs.

scholarly journals Hepatitis

2001 ◽  
Vol 12 (6) ◽  
pp. 329-331 ◽  
Author(s):  
Mel Krajden
Keyword(s):  
Public Health ◽  
Liver Transplantation ◽  
Liver Disease ◽  
Hepatitis C ◽  
Public Health Perspective ◽  
End Stage Liver Disease ◽  
B Virus ◽  
At Risk Populations ◽  
Chronic Hbv ◽  
End Stage

Worldwide, approximately 170 million people are chronically infected with hepatitis C virus (HCV) and another 350 million individuals are chronically infected with hepatitis B virus (HBV) (1,2). Canada is estimated to have 240,000 to 300,000 HCV and 200,000 to 280,000 HBV chronic carriers (3,4). Without intervention, over multiple decades, approximately 15% to 30% of chronic HBV- and HCV-infected individuals will develop cirrhosis, end-stage liver disease or liver cancer, or will require liver transplantation (1,2,5). From a public health perspective, the major challenge is how best to avoid acute (incident) infections in at-risk populations, and for those already chronically infected, how to prevent consequent morbidity and mortality.

Chronic HBV-related liver disease

2008 ◽  
Vol 29 (1-2) ◽  
pp. 72-84 ◽  
Author(s):  
Mario Rizzetto ◽  
Alessia Ciancio
Keyword(s):  
Liver Disease ◽  
Chronic Hbv ◽  
Related Liver Disease
Sign in / Sign up

Export Citation Format

Share Document